Tryptamine Therapeutics’ TRP-8803 Advances After Positive Study

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics has successfully completed a Phase 1b study confirming that their IV-infused psilocin formulation, TRP-8803, offers effective, rapid onset of the psychedelic state in obese subjects, comparable to non-obese individuals. This innovative treatment showcases advantages over oral psilocybin, such as precise dosage control and faster effects, bolstering its potential for future clinical trials targeting conditions like Binge Eating Disorder. The study’s results suggest TRP-8803 may provide a scalable solution with significant neuroplastic benefits, driving interest in the company’s continued development efforts.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.